Global Analysis Links Over 2 Million Annual Cancers to Preventable Infections
A worldwide analysis found that infectious agents caused approximately 2.3 million new cancer cases in 2024, representing 12% of all cancers globally. Five infections—Helicobacter pylori, human papillomavirus, hepatitis B virus, Epstein-Barr virus, and hepatitis C virus—accounted for nearly all infection-related cancers, with H. pylori and HPV causing the largest disease burden. The researchers emphasized that most major infectious causes already have highly effective prevention measures available, including vaccines, screening programs, and treatments.
The analysis identified 12 carcinogenic pathogens worldwide, though five organisms drove the vast majority of infection-related malignancies. Helicobacter pylori and human papillomavirus each caused approximately 750,000 cases, primarily manifesting as stomach and cervical cancers respectively. Hepatitis B and C viruses together accounted for roughly half a million cases, predominantly appearing as liver cancer, while Epstein-Barr virus contributed significantly to nasopharyngeal cancer development.
Geographic distribution of infection-driven cancers reveals stark disparities in disease burden. Eastern Asia bore the heaviest load, representing 42% of global cases and driven primarily by H. pylori and hepatitis B prevalence, while sub-Saharan Africa accounted for 25% of cases with human papillomavirus as the dominant pathogen. These regional variations underscore how local infection patterns and healthcare infrastructure shape cancer epidemiology.
The findings could substantially influence global cancer prevention priorities and resource allocation. Nations with existing vaccination programs and screening infrastructure may see incremental public health gains, while resource-limited regions facing high infection burdens could face implementation challenges. Health systems may need to develop regionally tailored prevention strategies rather than applying uniform approaches, potentially widening disparities unless accompanied by strengthened healthcare capacity and equitable vaccine distribution in under-resourced areas.